<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only [not the fosphenytoin] by the cytotoxic, or risk of increase of the toxicity or loss of the effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="FOLATES" code="V03-" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FUROSEMIDE" rxcui="460">
<ATC code="C03CA01" />
<ATC code="C03CB01" />
<ATC code="C03EB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the diuretic effect which can reach 50%</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Overdose of phenytoin (decrease of its metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="METYRAPONE" rxcui="6923">
<ATC code="V04CD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the antiarrythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the phenytoin or the fosphenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)

In cases of previous treatment with the phenytoin and the addition of phenobarbital or of primidone, unpredictable changes:

--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.

--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="J01EB05" />
<ATC code="S01AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="D06BA04" />
<ATC code="J01EB02" />
<ATC code="S01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
<ATC code="J01EE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism). </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammoniemia, with increased risk of encephalopathy

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
